Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Influenza

Free Subscription 09.06.2025 3 BMC Pediatr 1 J Gen Virol 13 J Infect Dis 3 J Virol 2 Pediatrics 1 PLoS Comput Biol 33 PLoS One 1 Proc Natl Acad Sci U S A 15 Vaccine

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMC Pediatr

1. ALRASHED R, Almeshawi I, Alshammari A, Alhamoud W, et al
   Burden of bronchiolitis post-COVID-19 pandemic in children less than 2 years old in 2021-2024: experience from a tertiary center in Saudi Arabia.
   BMC Pediatr. 2025;25:453.
   PubMed         Abstract available
   
   
2. BIGLARI HN, Ahmadi A, Alidousti K, Pouredalati M, et al
   Growth in the first two years in children born to mothers infected with COVID-19 during pregnancy: a cohort study.
   BMC Pediatr. 2025;25:448.
   PubMed         Abstract available
   
   
3. CHENG J, Wu Y, Ma H, Tang M, et al
   C-reactive protein and serum amyloid A protein as complementary biomarkers in differentiating viral and bacterial community-acquired pneumonia in children.
   BMC Pediatr. 2025;25:445.
   PubMed         Abstract available
   
   

   
   J Gen Virol

4. CAPELASTEGUI F, Goldhill DH
   H5N1 2.3.4.4b: a review of mammalian adaptations and risk of pandemic emergence.
   J Gen Virol. 2025;106:002109.
   PubMed         Abstract available
   
   

   
   J Infect Dis

5. LU Y, Matuska K, McEvoy R, Izurieta HS, et al
   Relative Effectiveness and Waning of a Third Dose of mRNA COVID-19 Vaccine in Medicare Beneficiaries Aged 65 Years and Older during the BA.1/BA.2 Omicron Period.
   J Infect Dis. 2024 Oct 15:jiae503. doi: 10.1093.
   PubMed         Abstract available
   
   
6. OZTURK A, Chan M, Khan JR, Hu N, et al
   Clinical Characteristics and In-hospital Outcomes Associated With Respiratory Syncytial Virus vs Other Viral Acute Lower Respiratory Infections in Hospitalized Children Younger Than 2 Years.
   J Infect Dis. 2025;231:1309-1317.
   PubMed         Abstract available
   
   
7. HOUDE L, Law AW, Averin A, Weycker D, et al
   Annual Clinical and Economic Burden of Medically Attended Lower Respiratory Tract Illnesses Due to Respiratory Syncytial Virus Among US Infants Aged <12 Months.
   J Infect Dis. 2025;231:1318-1326.
   PubMed         Abstract available
   
   
8. URCHUEGUIA-FORNES A, Munoz-Quiles C, Mira-Iglesias A, Lopez-Lacort M, et al
   Ten-Year Surveillance of Respiratory Syncytial Virus Hospitalizations in Adults: Incidence Rates and Case Definition Implications.
   J Infect Dis. 2025;231:e830-e839.
   PubMed         Abstract available
   
   
9. RIEDMANN U, Chalupka A, Richter L, Sprenger M, et al
   Estimates of SARS-CoV-2 Infections and Population Immunity After the COVID-19 Pandemic in Austria: Analysis of National Wastewater Data.
   J Infect Dis. 2025;231:e921-e928.
   PubMed         Abstract available
   
   
10. ZIDAR DA, McComsey GA, Anthony DD, McDaniel J, et al
    Distinct Cytokine Patterns Identify Acute and Convalescent Myocardial Involvement After Coronavirus Disease 2019: A Multicohort Biomarker Study.
    J Infect Dis. 2025;231:e918-e920.
    PubMed         Abstract available
    
    
11. LENNOL MP, Garcia-Ayllon MS, Aviles-Granados C, Trasciatti C, et al
    Increased Cerebrospinal Fluid Angiotensin-Converting Enzyme 2 Fragments as a Read-Out of Brain Infection in Patients With COVID-19 Encephalopathy.
    J Infect Dis. 2025;231:e929-e940.
    PubMed         Abstract available
    
    
12. DI GERMANIO C, Marques de Menezes EG, Clevenger R, Rines I, et al
    Viral and Immune Factors Associated With COVID-19 Outcome in the C3PO Trial of Convalescent Plasma.
    J Infect Dis. 2025;231:1198-1209.
    PubMed         Abstract available
    
    
13. BAUMGARDT M, Obermayer B, Balazs A, Lowa A, et al
    SARS-CoV-2 Infection of Human Lung Air-Liquid Interface Cultures Reveals Basal Cells as Relevant Targets.
    J Infect Dis. 2025;231:1210-1220.
    PubMed         Abstract available
    
    
14. HEDBERG P, van der Werff SD, Naucler P
    The effect of COVID-19 vaccination on the risk of persistent post COVID-19 condition: Cohort study.
    J Infect Dis. 2025 Mar 12:jiaf133. doi: 10.1093.
    PubMed         Abstract available
    
    
15. REICHERZ F, Vineta Paramo M, Bone JN, Lavoie A, et al
    Recovery of Antibody Immunity After a Resurgence of Respiratory Syncytial Virus Infections.
    J Infect Dis. 2025;231:e840-e845.
    PubMed         Abstract available
    
    
16. ROSTAD CA, Campbell JD, Paulsen GC, Schnyder Ghamloush S, et al
    Evaluation of Cellular Immune Responses After mRNA-1273 Vaccination in Children 6 Months to 11 Years of Age.
    J Infect Dis. 2025 Mar 22:jiaf144. doi: 10.1093.
    PubMed         Abstract available
    
    
17. KING LM, Bruxvoort KJ, Tartof SY, Lewnard JA, et al
    Pediatric antibiotic use associated with respiratory syncytial virus and influenza in the United States, 2008-2018.
    J Infect Dis. 2025 Jun 7:jiaf309. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Virol

18. COGGON A, Lopes S, Simon G, Arendsee Z, et al
    Quantifying the zoonotic risk profile of European influenza A viruses in swine from 2010 to 2020 inclusive.
    J Virol. 2025 Jun 4:e0030625. doi: 10.1128/jvi.00306.
    PubMed         Abstract available
    
    
19. ROBINSON-MCCARTHY LR, Zirckel KE, Simmons HC, Le Sage V, et al
    A replicating recombinant vesicular stomatitis virus model for dairy cattle H5N1 influenza virus glycoprotein evolution.
    J Virol. 2025 Jun 4:e0038925. doi: 10.1128/jvi.00389.
    PubMed         Abstract available
    
    
20. SEIBERT B, Caceres CJ, Gay LC, Shetty N, et al
    Air-liquid interface model for influenza aerosol exposure in vitro.
    J Virol. 2025 Jun 3:e0061925. doi: 10.1128/jvi.00619.
    PubMed         Abstract available
    
    

    
    Pediatrics

21. CHUA KP, Constantin J, Kenney GM, Conti RM, et al
    Changes in Chronic Medication Dispensing to Children and Young Adults During Medicaid Unwinding.
    Pediatrics. 2025;155:e2024070380.
    PubMed         Abstract available
    
    
22. IRVING SA, Crane B, Weintraub ES, Patel SA, et al
    Infant Respiratory Syncytial Virus Immunization Coverage in the Vaccine Safety Datalink: 2023-2024.
    Pediatrics. 2025 May 6:e2024070240. doi: 10.1542/peds.2024-070240.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

23. CHEN S, Venkatesan S, Arnetorp S, Bergenheim K, et al
    Features influencing the health and economic impact of preventing COVID-19 in immunocompromised individuals.
    PLoS Comput Biol. 2025;21:e1013072.
    PubMed         Abstract available
    
    

    
    PLoS One

24. CHEN Y, Dean KJ, Fenske GJ, Murphy SI, et al
    Rapid risk assessment to address emerging concerns of HPAI in raw and pasteurized milk.
    PLoS One. 2025;20:e0322948.
    PubMed         Abstract available
    
    
25. ISSA E, Lahoud R, Abi-Gerges A, Salameh P, et al
    Breast cancer screening practices during a multifaceted crisis: Data from Lebanon.
    PLoS One. 2025;20:e0325604.
    PubMed         Abstract available
    
    
26. SALMAM I, Dube MO, Zahouani I, Ramos A, et al
    The impact of long COVID on physical and cardiorespiratory parameters: A systematic review.
    PLoS One. 2025;20:e0318707.
    PubMed         Abstract available
    
    
27. CHANG LF, Lee PH, Dowding D, Hsieh CJ, et al
    Integrating information and communication technology into nursing practice for resilience: A cross-sectional quantitative study.
    PLoS One. 2025;20:e0324865.
    PubMed         Abstract available
    
    
28. NISAR N, Badar N, Safdar I
    Assessing influenza activity variations in the Asian region during the pre- and post-pandemic period (2017-2023).
    PLoS One. 2025;20:e0323465.
    PubMed         Abstract available
    
    
29. SHATALOV PA, Raygorodskaya MP, Shinkarkina AP, Traspov AA, et al
    Adaptation of PCR-based library preparation for MGI platform for cancer mutation testing in clinical setting.
    PLoS One. 2025;20:e0323685.
    PubMed         Abstract available
    
    
30. WULLER S, Singer NG, Lewis C, Karlson EW, et al
    Severity of acute SARS-CoV-2 infection and risk of new-onset autoimmune disease: A RECOVER initiative study in nationwide U.S. cohorts.
    PLoS One. 2025;20:e0324513.
    PubMed         Abstract available
    
    
31. SNYDER RL, White KA, Anderson LE, Cochran RL, et al
    Exploring burnout and staff turnover among acute care nurses and physicians during the COVID-19 pandemic: Insights from a qualitative assessment.
    PLoS One. 2025;20:e0319390.
    PubMed         Abstract available
    
    
32. YELVERTON V, Ostermann J, Yarrington ME, Weinhold AK, et al
    Telehealth and in-person HIV care during the COVID-19 pandemic at a large academic medical center in North Carolina.
    PLoS One. 2025;20:e0320911.
    PubMed         Abstract available
    
    
33. CARAZO S, Skowronski DM, Brousseau N, Guay CA, et al
    Monovalent mRNA XBB.1.5 vaccine effectiveness against COVID-19 hospitalization in Quebec, Canada: Impact of variant replacement and waning protection during 10-month follow-up.
    PLoS One. 2025;20:e0325269.
    PubMed         Abstract available
    
    
34. ANWAR MR, Akhter R, Stukel TA, Chung H, et al
    Association of physician-delivered virtual care near the end of life with healthcare use outcomes: A national population-based study of Canadians.
    PLoS One. 2025;20:e0324898.
    PubMed         Abstract available
    
    
35. DA SILVA VIANA L, Chung Filho AA, Monteiro GTR, Sobral A, et al
    The interaction between cancer and COVID-19: Risk factors and targeted interventions.
    PLoS One. 2025;20:e0319970.
    PubMed         Abstract available
    
    
36. GAMS M, Marinko A, Rescic N, Vodopija A, et al
    Balancing health and socioeconomic impacts: A uniform framework for evaluating non-pharmaceutical interventions.
    PLoS One. 2025;20:e0324232.
    PubMed         Abstract available
    
    
37. HAO S, Velasquez EE, Pearson WS, Hoover KW, et al
    Primary care screening for sexually transmitted infections in the United States from 2019 to 2021.
    PLoS One. 2025;20:e0325097.
    PubMed         Abstract available
    
    
38. MONDOUX S, Battaglia F, Gayowsky A, Clayton N, et al
    A retrospective evaluation of access equity in virtual care during the COVID-19 pandemic: A 2-year review and comparison of visits in Ontario, Canada.
    PLoS One. 2025;20:e0323303.
    PubMed         Abstract available
    
    
39. PRATHER JF, McCoy D, Heaney A, Smith LA, et al
    Student perceptions of COVID-19 challenges affecting student motivation, well-being, and success in undergraduate education.
    PLoS One. 2025;20:e0324832.
    PubMed         Abstract available
    
    
40. STASSINOS J, Anderson T, Zufle A
    Towards using Tweet sentiment for infectious disease detection.
    PLoS One. 2025;20:e0325166.
    PubMed         Abstract available
    
    
41. LUOTO R, Laatikainen-Raussi V, Mjosund KE, Valtonen M, et al
    Viral acute respiratory illnesses in elite athletes: A 12-month controlled follow-up study.
    PLoS One. 2025;20:e0322283.
    PubMed         Abstract available
    
    
42. RAMIREZ-SOTO MC, Arroyo-Hernandez H
    Changes in HIV incidence during the COVID-19 pandemic (2020-22) compared with the pre-pandemic period (2015-19) in Peru: An observational study.
    PLoS One. 2025;20:e0324784.
    PubMed         Abstract available
    
    
43. NOPKUESUK N, Klamrak A, Nabnueangsap J, Narkpuk J, et al
    Hydroethanolic extract of Schinus terebinthifolia as a promising source of anti-influenza agents: Phytochemical profiling, cheminformatics, molecular docking and dynamics simulations.
    PLoS One. 2025;20:e0324990.
    PubMed         Abstract available
    
    
44. CHAN R, Brady B, Zou J, McMullan M, et al
    Exploring the feasibility, effectiveness, and acceptability of telehealth for delivering a pain management group program: A retrospective study.
    PLoS One. 2025;20:e0325298.
    PubMed         Abstract available
    
    
45. YAN H, Hu S, Zhang H, Zhou Y, et al
    Optimized tacrolimus dosing strategy in kidney transplant recipients receiving nirmatrelvir-ritonavir for COVID-19.
    PLoS One. 2025;20:e0309875.
    PubMed         Abstract available
    
    
46. BRAESEMANN F, Kluge J, Lorenz H
    How have urban housing preferences developed in response to the COVID-19 pandemic? A case study of Vienna.
    PLoS One. 2025;20:e0322629.
    PubMed         Abstract available
    
    
47. VILLAR J, Macaira P, Baiao FA
    Lessons learned from the COVID-19 pandemic in Latin America: A Data Science standpoint.
    PLoS One. 2025;20:e0324171.
    PubMed         Abstract available
    
    
48. MBOGORI E, Thiongo K, Deng HY, Gikunyu CW, et al
    SARS-COV-2 mutations in North Rift, Kenya.
    PLoS One. 2025;20:e0325133.
    PubMed         Abstract available
    
    
49. KIM J, Lee S, Weir P
    Long-COVID is associated with increased absenteeism from work.
    PLoS One. 2025;20:e0325280.
    PubMed         Abstract available
    
    
50. WANG Z, Jin Y, Tian W, Zhou X, et al
    The various effect of social isolation on depression risk among old population in China during covid-19 pandemic: A population based survey.
    PLoS One. 2025;20:e0325595.
    PubMed         Abstract available
    
    
51. EID R, Sayad A, Samaan W, Salameh P, et al
    Prevalence of influenza A and B and respiratory syncytial virus infections before and during COVID-19 pandemic in the pediatric population in Lebanon: A retrospective study.
    PLoS One. 2025;20:e0325001.
    PubMed         Abstract available
    
    
52. KOSTINOV M, Svitich O, Chuchalin A, Gajnitdinova V, et al
    Phagocytic activity of blood monocytes and neutrophils in moderate COVID-19 patients and impact of immune therapy with bacterial lysates.
    PLoS One. 2025;20:e0324987.
    PubMed         Abstract available
    
    
53. LEE M, Park BK, Shin DH, Oh HS, et al
    Long-term pulmonary sequelae and convalescent immune reactions in mild to moderate COVID-19 patients during the active treatment era.
    PLoS One. 2025;20:e0325379.
    PubMed         Abstract available
    
    
54. ZWIERS LC, Brakenhoff TB, Goodale BM, Veen D, et al
    Remote early detection of SARS-CoV-2 infections using a wearable-based algorithm: Results from the COVID-RED study, a prospective randomised single-blinded crossover trial.
    PLoS One. 2025;20:e0325116.
    PubMed         Abstract available
    
    
55. HARTVIGSEN G, Dimitroff Y
    Modeling the SARS-CoV-2 epidemic and the efficacy of different vaccines across different network structures.
    PLoS One. 2025;20:e0325129.
    PubMed         Abstract available
    
    
56. LUMKUL L, Tanasombatkul K, Nitikaroon P, Morasert T, et al
    In-hospital mortality outcomes of favipiravir in patients with moderate to severe COVID-19 infection: An emulated target trial using real-world data from the largest field hospital in Thailand.
    PLoS One. 2025;20:e0324903.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

57. HUANG P, Almquist ZW, Butts CT
    Endogenous competition and the underrealized reproduction of infectious diseases.
    Proc Natl Acad Sci U S A. 2025;122:e2502676122.
    PubMed         Abstract available
    
    

    
    Vaccine

58. STOUTEN V, Van Evercooren I, Vernemmen C, Braeye T, et al
    Averted mortality by COVID-19 vaccination in Belgium between 2021 and 2023.
    Vaccine. 2025;60:127290.
    PubMed         Abstract available
    
    
59. DAVE E, Culhane JF, Lundsberg LS, Partridge C, et al
    Trends in Tdap and influenza vaccination in pregnancy relative to the coronavirus disease-19 pandemic.
    Vaccine. 2025;61:127329.
    PubMed         Abstract available
    
    
60. YADAV G, Dandu H, Malhotra HS, Jain A, et al
    COVID-19 vaccination and utility of booster dose: A community-based cross-sectional study.
    Vaccine. 2025;60:127325.
    PubMed         Abstract available
    
    
61. NASREEN S, Jiang Y, Lu H, Lee A, et al
    Risk of Guillain-Barre syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study.
    Vaccine. 2025;60:127291.
    PubMed         Abstract available
    
    
62. LEE N, Nguyen L, Nasreen S, Austin PC, et al
    Limited durability of protection conferred by XBB.1.5 vaccines against omicron-associated severe outcomes among community-dwelling adults, Ontario, Canada.
    Vaccine. 2025;60:127300.
    PubMed         Abstract available
    
    
63. ALSHURMAN BA, Majowicz SE, Grindrod K, Goh J, et al
    Understanding the shift in COVID-19 vaccine hesitancy and its associated factors for primary and booster doses among university students: A cross-sectional study.
    Vaccine. 2025;59:127296.
    PubMed         Abstract available
    
    
64. MOHAMED Y, Luey E, Kata ', Tukia O, et al
    "The only vaccine that we really question is the new vaccine": A qualitative exploration of the social and behavioural drivers of human papillomavirus (HPV) vaccination in Tonga.
    Vaccine. 2025;59:127280.
    PubMed         Abstract available
    
    
65. GANDHI K, Vijay Y, Page K, Dahari H, et al
    Challenges in coverage of future hepatitis C vaccines: Review and potential solutions.
    Vaccine. 2025;59:127256.
    PubMed         Abstract available
    
    
66. SURI RK, Maugeais D, Maithal K
    COVID-19 pandemic: A multidimensional analysis and the strategic role played by developing countries vaccine manufacturers.
    Vaccine. 2025;59:127271.
    PubMed         Abstract available
    
    
67. HASAN Z, Masood KI, Qaiser S, Kanji A, et al
    Comparative study of humoral and cellular immunity against SARS-CoV-2 induced by different COVID-19 vaccine types: Insights into protection against wildtype, Delta and JN.1 omicron strains.
    Vaccine. 2025;59:127270.
    PubMed         Abstract available
    
    
68. FITZPATRICK T, Yamoah P, Summerby-Murray D, Cowan J, et al
    Neurological adverse events following COVID-19 vaccination among Canadians referred to the special immunization clinic network.
    Vaccine. 2025;59:127254.
    PubMed         Abstract available
    
    
69. NHAM E, Song JY, Sohn JW, Choi WS, et al
    Real-world effectiveness of COVID-19 XBB.1.5 monovalent mRNA vaccine: Analysis over nine months.
    Vaccine. 2025;59:127275.
    PubMed         Abstract available
    
    
70. SCHAFFER AL, Hulme WJ, Horne E, Parker EPK, et al
    Effect of the 2022 COVID-19 booster vaccination campaign in people aged 50 years in England: Regression discontinuity analysis in OpenSAFELY-TPP.
    Vaccine. 2025;59:127257.
    PubMed         Abstract available
    
    
71. FURUSE Y, Tabuchi T
    Impact of COVID-19 vaccination by implementation timing and coverage rate in relation to misinformation prevalence in Japan.
    Vaccine. 2025;59:127273.
    PubMed         Abstract available
    
    
72. KIM C, Lee D, Oh YW, Jung SJ, et al
    Association between parental and child influenza vaccination: A national health survey analysis.
    Vaccine. 2025;61:127345.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge.